Better Biopharma

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/22/b6/ed/22b6eddf-5c3e-269c-a1d1-a030f26c3df8/mza_18271531636826187750.jpg/600x600bb.jpg

Better Biopharma

Tyler Menichiello

10 episodes

4 days ago

In this episode of "Better Biopharma," host Tyler Menichiello is joined by Bonum Therapeutics' chief scientific officer, Diane Hollenbaugh, Ph.D., and chief business officer, Neela Patel, Ph.D. They talk about the inherent challenges of developing complex molecules like conditionally active biologics, sharing advice on CMC strategy, analytical methodology, and working with contract manufacturing and development partners. Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenic...

Life Sciences

Science

RSS

All content for Better Biopharma is the property of Tyler Menichiello and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Life Sciences

Science

Episodes (10/10)

Better Biopharma

Navigating The Complexity of Conditionally Active Biologics With Bonum Therapeutics' Diane Hollenbaugh, Ph.D., and Neela Patel, Ph.D.

4 days ago

47 minutes

Better Biopharma

Developing Antibodies To Block Neuroinflammation With MindImmune's Stevin Zorn, Ph.D.

In this episode of "Better Biopharma," host Tyler Menichiello is joined by MindImmune's president and CEO, Stevin Zorn, Ph.D. They discuss the development of the company's lead candidate, MITI-101, a monoclonal antibody designed to prevent peripheral immune cells from entering the brain and driving neuroinflammation linked to Alzheimer's disease. Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/ Keep up with everything biomanufacturing at Bioprocess Online: http...

2 weeks ago

44 minutes

Better Biopharma

Engineering Bacterial Vector-Based Immunotherapies With OS Therapies’ Paul Romness and Robert Petit, Ph.D.

In this episode of “Better Biopharma,” host Tyler Menichiello is joined by OS Therapies’ CEO, Paul Romness, and chief medical and scientific officer, Robert Petit, Ph.D. The three discuss the development and manufacturing of the company’s lead asset, OST-HER2, a Listeria-based immunotherapy for osteosarcoma. They also explain the unique CMC challenges around developing a safe bacterial vector. Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/ Keep up with everyt...

1 month ago

36 minutes

Better Biopharma

How J&J Is Tackling Alzheimer's Disease With Fiona Elwood, Ph.D.

In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Fiona Elwood, Ph.D., VP and Neurodegeneration Disease Area Stronghold Leader at Johnson & Johnson. The two talk about J&J’s end-to-end organizational structure and its modality-agnostic approach to treating Alzheimer’s disease. Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/ Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/ Subscri...

1 month ago

32 minutes

Better Biopharma

CDMO Hunger Games And The State Of Biotech With Siren Biotechnology's Nicole Paulk, Ph.D.

In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Nicole Paulk, Ph.D., CEO and founder of Siren Biotechnology, a company developing a universal AAV immuno-gene therapy for cancer. They discuss the company’s decision to switch from plasmids to producer cell lines (PCLs) in production, the current funding environment for cell and gene therapies (CGTs), how companies are innovating and doing more with less, and the unconventional head-to-head competition that determined ...

2 months ago

1 hour

Better Biopharma

Delivering Biologics To The Brain With Adaptin Bio's Michael Roberts, Ph.D., and Duke University's Mustafa Khasraw, MD

In this episode of "Better Biopharma," host Tyler Menichiello is joined by Adaptin Bio's CEO, co-founder, and president, Michael Roberts, Ph.D., and Duke University's Mustafa Khasraw, MD. They discuss Adaptin's Brain Bispecific T-cell Engager (BRiTE) platform, its clinical potential to deliver therapeutic T cells across the blood-brain barrier, and the development and manufacturing challenges behind the company's lead asset, APTN-101. Follow Tyler Menichiello on LinkedIn: https://www.li...

2 months ago

36 minutes

Better Biopharma

Developing An In Vivo CAR-T With Interius BioTherapeutics' Sianny Christanti and Babu Medi, Ph.D.

On this episode of Better Biopharma, Interius BioTherapeutics’ Sianny Christanti and Babu Medi, Ph.D., explain how the company is re-engineering a lentiviral vector to enable INT2104, its off-the-shelf, in vivo CAR T-cell therapy. They discuss the vector's design and its manufacturability, as well as the analytical and regulatory challenges of bringing this first-in-human therapy to the clinic. Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/ Keep up with every...

2 months ago

48 minutes

Better Biopharma

Functional Antibody Screening With Abalone Bio's Richard Yu, Ph.D.

In this episode of "Better Biopharma," Abalone Bio's CEO and co-founder, Richard Yu, Ph.D., explains how the company's functional antibody selection technology (FAST) platform differs from traditional affinity screening. Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/ Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/ Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions

3 months ago

43 minutes

Better Biopharma

PILOT: Introducing Better Biopharma

How can the biopharmaceutical industry improve? Join Bioprocess Online's Tyler Menichiello as he explores this question through a series of interviews with experts and leaders from across the space. Subscribe for biweekly, in-depth conversations with the brightest minds in biotech to learn how they're moving the needle to make better medicines and optimize manufacturing. Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/ Keep up with everything biomanufacturing a...

3 months ago

2 minutes

Better Biopharma

Using Algae To Manufacture Oral Biologics With Lumen Bioscience's Craig Behnke, Ph.D.

Lumen Bioscience is putting the farm in biopharma — literally! In this episode of Better Biopharma, Lumen's EVP of production and development, Craig Behnke, Ph.D., explains the company's chlorophyll-powered approach to bioprocessing using photosynthetic cyanobacteria. Check out Behnke's past appearance on Business Of Biotech: https: //www.lifescienceleader.com/doc/democratizing-biologics-with-lumen-bioscience-s-brian-finrow-j-d-craig-behnke-ph-d-0002 Follow Tyler Menichiello on LinkedIn:...

3 months ago

44 minutes